



## Precision Medicine: Scope, Integration, and Future Directions

Felic. S\*<sup>1</sup>., Naveen.V<sup>2</sup>

<sup>1</sup>Doctor of pharmacy, JKKMMRF'S Annai Jkk Sampoorani Ammal College of Pharmacy, Komarapalayam, Tamilnadu, India.

<sup>2</sup>Doctor of pharmacy, JKKMMRF'S Annai Jkk Sampoorani Ammal College of Pharmacy, Komarapalayam, Tamilnadu, India.

Received: 2024-10-05

Revised: 2024-10-15

Accepted: 2024-10-20

### ABSTRACT

**Background:** Precision medicine aims to tailor healthcare by considering genetic, environmental, and lifestyle factors unique to each individual. This field represents a transformative approach to disease prevention, diagnosis, and treatment. **Objective:** To explore the scope, integration, challenges, and future directions of precision medicine, emphasizing its impact on various health sectors. **Methods:** A review of current literature and advancements in precision medicine was conducted. Key aspects, including technological developments, stakeholder perspectives, and ethical considerations, were analyzed. **Results:** Precision medicine integrates data science, clinical care, and patient-specific information to optimize outcomes. Emerging technologies such as artificial intelligence and machine learning have enhanced disease diagnosis and treatment personalization. However, challenges remain, including ethical, technical, and economic barriers. Additionally, the global adoption of precision medicine varies, with resource-limited settings facing significant challenges. **Conclusion:** Precision medicine holds the potential to revolutionize healthcare through individualized treatment plans. While technological advancements offer significant benefits, widespread implementation requires addressing challenges related to cost, ethical considerations, and equitable access.

**KEYWORDS:** AI & ML (Artificial Intelligence & Machine Learning), Precision Medicine, Personalized Treatment, Genomics, Pharmacogenomics, CRISPR/Cas9.

### INTRODUCTION

Precision medicine is an evolving field that aims to tailor healthcare to individual patients based on their unique characteristics, including genetic, environmental, and lifestyle factors. This approach seeks to improve the prevention, diagnosis, and treatment of diseases by leveraging large-scale data and advanced technologies [1].

#### Definition and Scope of Precision Medicine

Precision medicine involves the derivation of novel taxonomies based on deep phenotyping, which includes clinical, lifestyle, genetic, and biomarker information [2]. It is a process that individualizes healthcare by using up-to-date patient information to guide decisions related to treatment, such as drug selection, dosage, and timing [3].

#### Integration and Impact

Precision medicine integrates data science, analytics, and clinical care to optimize patient outcomes and improve healthcare delivery systems [4]. It is an integrative approach that considers an individual's genetics, lifestyle, and exposures to tailor cardiovascular disease prevention and treatment [5].

#### Broader Scope and Challenges

The field spans various scientific areas, including drug discovery, genetics/genomics, health communication, and causal inference, all supporting evidence-based decision-making [6]. Precision medicine must address technical, scientific, policy, ethical, and social challenges, requiring new mathematical techniques for robust and interpretable data analysis [7].




## Stakeholder Perspectives and Value

Precision medicine affects all stakeholders in the healthcare system, from individual patients to society, and requires consensus on value assessment frameworks to ensure efficient and practical implementation [8]. The adoption of precision medicine into clinical practice has lagged despite the rapid discovery of disease-causing and drug-response genetic variants [9].

## Comprehensive Approach

Precision medicine should not be limited to biological and technical components but should also consider environmental, socio-economic, psychological, and biological determinants for a more personalized approach to health [10].



**Fig.1. This diagram illustrates the overall process of precision medicine, from data collection to improved patient outcomes.**

Precision medicine represents a transformative approach to healthcare, focusing on the individualization of treatment based on comprehensive data analysis. It integrates various scientific disciplines and requires collaboration among stakeholders to address the associated challenges. By considering a wide range of determinants, precision medicine aims to provide more precise and effective healthcare, ultimately improving patient outcomes [11].

## Historical Context of Precision Medicine

The principles of precision medicine can be traced back to ancient medical practices, particularly in Greek medicine, which emphasized individualized treatment based on the unique characteristics of each patient [12]. However, modern precision medicine gained momentum with the Precision Medicine Initiative, launched in 2015, aiming to revolutionize healthcare through genomic data and personalized treatment strategies [13].

## Technological Advancements in Precision Medicine

Technological advancements, including the use of artificial intelligence (AI) and machine learning (ML), have vastly improved the capabilities of precision medicine. AI models, such as logistic regression and deep learning, have enhanced disease diagnosis, prognosis, and treatment response predictions by processing large datasets like electronic health records and genetic data [14]. Additionally, high-throughput sequencing technologies have enabled comprehensive genomic testing, identifying markers for diseases and guiding targeted therapies [15].

## Pharmacogenomics in Precision Medicine

Pharmacogenomics, a key component of precision medicine, studies how genes affect an individual's response to drugs. This area focuses on optimizing drug efficacy and reducing adverse drug reactions based on the patient's genetic profile [16]. For example,



genetic variants in enzymes responsible for drug metabolism are used to personalize drug prescribing, significantly improving treatment outcomes [17].

### Ethical, Legal, and Social Issues

Precision medicine introduces significant ethical, legal, and social challenges. These include concerns over genetic privacy, informed consent, and the potential misuse of genetic information by employers or insurers [18]. The lack of diverse representation in genomic databases has also raised concerns about equity in access to precision medicine, particularly for underrepresented populations [19].

### Economic and Policy Considerations

The economic implications of precision medicine are substantial, with the potential to both improve healthcare outcomes and increase healthcare costs due to the expense of genetic testing and targeted therapies. Policymakers must address these economic challenges to ensure equitable access to precision medicine, including the development of reimbursement strategies and regulatory frameworks that support its integration into standard clinical practice [20].




Fig.2. Graphical diagram representing key concepts in precision medicine

### Future Perspectives

The future of precision medicine is likely to involve the integration of digital health technologies, such as wearable devices, with genomic data to provide real-time, personalized healthcare interventions [21]. Emerging fields like microbiome research and CRISPR gene editing also hold promise for advancing precision medicine by providing new tools for disease prevention and treatment [22]. However, continued advancements will require overcoming existing barriers, such as ethical concerns, high costs, and technological limitations [23].

As precision medicine continues to evolve, it holds the potential to transform the healthcare system by providing more personalized, effective treatments. However, realizing its full potential will require addressing numerous challenges, including ethical, economic, and technological barriers. By focusing on interdisciplinary collaboration and equitable access, precision medicine can lead to significant improvements in patient care and healthcare outcomes [24].



### **Applications of Precision Medicine in Oncology**

Precision medicine has had a profound impact on the field of oncology. By utilizing genomic profiling and targeted therapies, oncologists can now identify specific mutations within a patient's tumor and select therapies that directly target those mutations. This approach has led to significant improvements in the treatment of cancers such as breast, lung, and colorectal cancers [25]. Immunotherapy, particularly immune checkpoint inhibitors, is another area where precision medicine has made great strides, allowing for personalized cancer treatments that enhance the body's immune response to cancer cells [26].

### **Precision Medicine in Cardiovascular Disease**

In the field of cardiovascular disease, precision medicine has been instrumental in improving prevention, diagnosis, and treatment strategies. By analyzing genetic, environmental, and lifestyle factors, precision medicine allows for the identification of individuals at higher risk for conditions such as hypertension, coronary artery disease, and arrhythmias [27]. Pharmacogenomics has also played a critical role in tailoring cardiovascular treatments, particularly in the dosing of anticoagulants and statins, to minimize adverse effects and optimize patient outcomes [28].

### **Role of Big Data in Precision Medicine**

Big data analytics is central to the success of precision medicine. The ability to analyze large datasets, including genomic sequences, electronic health records, and environmental exposure data, has enabled researchers and clinicians to develop more accurate predictive models for disease risk and treatment response [29]. However, the integration of big data into precision medicine presents several challenges, including data privacy concerns, the need for advanced computational tools, and the development of standardized protocols for data sharing and analysis [30].

### **Challenges in Implementing Precision Medicine**

The implementation of precision medicine faces several hurdles, including the high costs associated with genetic testing and sequencing, as well as the limited availability of precision medicine in underserved populations [31]. Furthermore, healthcare professionals often lack sufficient training in genomics and data science, which hinders the widespread adoption of precision medicine in clinical settings [32]. To overcome these challenges, there is a growing need for educational initiatives that equip healthcare providers with the necessary skills to implement precision medicine effectively [33].

### **Collaboration and Interdisciplinary Approach**

The success of precision medicine relies heavily on interdisciplinary collaboration among geneticists, data scientists, clinicians, and bioethicists. By fostering collaboration across these fields, precision medicine can continue to evolve and provide increasingly effective, personalized healthcare solutions [34]. The development of large, collaborative research networks that facilitate data sharing and the integration of diverse datasets is essential for advancing the field [35].

### **Global Impact of Precision Medicine**

The global adoption of precision medicine varies significantly across regions, with high-income countries leading the way in the implementation of personalized treatments. However, low- and middle-income countries face significant barriers, including limited access to advanced technologies, insufficient healthcare infrastructure, and economic constraints [36]. International collaborations and initiatives, such as the Global Alliance for Genomics and Health, aim to bridge these gaps by promoting the equitable distribution of precision medicine resources and knowledge [37].

### **Education and Training in Precision Medicine**

A critical barrier to the widespread adoption of precision medicine is the current gap in education and training among healthcare professionals. Many physicians lack adequate training in genetics, genomics, and data interpretation, which are essential components of precision medicine [38]. To bridge this gap, medical education curricula must evolve to incorporate these fields, ensuring that future healthcare providers are equipped with the knowledge and skills necessary to implement precision medicine effectively [39]. Continuing education programs for current practitioners are also vital to address this knowledge deficit and promote the integration of precision medicine into routine clinical practice [40].



## **The Role of Artificial Intelligence in Precision Medicine**

Artificial intelligence (AI) and machine learning (ML) have become indispensable tools in precision medicine, offering the ability to analyze vast datasets and identify patterns that would be impossible for humans to detect. AI is particularly useful in predictive analytics, where it can identify patients at high risk for diseases such as cancer or cardiovascular disease based on their genetic and environmental data [41]. Moreover, AI can assist in the design of personalized treatment plans, optimizing drug regimens and reducing the likelihood of adverse drug reactions [42]. However, the use of AI in healthcare raises ethical concerns, particularly regarding data privacy and the potential for algorithmic bias [43].

## **Ethical Considerations in Precision Medicine**

The implementation of precision medicine introduces numerous ethical challenges, particularly in relation to patient consent, data privacy, and the potential for discrimination based on genetic information [44]. Informed consent is a critical issue, as patients must understand the implications of genetic testing and data sharing. Furthermore, there is the risk that genetic information could be misused by employers, insurers, or even government agencies, leading to discrimination based on an individual's genetic predispositions [45]. To mitigate these risks, strong legal frameworks and ethical guidelines must be established to protect patients' rights while enabling the advancement of precision medicine [46].

## **Economic Challenges and Healthcare Disparities**

While precision medicine holds the potential to improve health outcomes, it also raises concerns about healthcare disparities, particularly in low- and middle-income countries. The high costs associated with genomic testing, data storage, and targeted therapies make it difficult for individuals in resource-limited settings to access precision medicine [47]. Additionally, healthcare systems in these regions may lack the infrastructure required to implement personalized treatments effectively [48]. International organizations and governments must work together to ensure that the benefits of precision medicine are accessible to all, regardless of economic status or geographic location [49].

Precision medicine represents a paradigm shift in healthcare, offering the potential to tailor treatments to individual patients based on their genetic, environmental, and lifestyle factors. While significant progress has been made in the fields of oncology, cardiovascular disease, and pharmacogenomics, there are still numerous challenges to overcome, including ethical considerations, healthcare disparities, and the need for improved education and training. As technology continues to advance and interdisciplinary collaborations grow, precision medicine is poised to become a central component of modern healthcare, improving patient outcomes and revolutionizing the way diseases are diagnosed and treated [50].

## **Future Outlook of Precision Medicine**

The future of precision medicine is closely tied to ongoing advancements in technology, particularly in the areas of genomics, artificial intelligence, and bioinformatics. As the cost of genomic sequencing continues to decrease, it is likely that precision medicine will become more accessible to a broader segment of the population [51]. Additionally, advancements in CRISPR technology and gene editing hold significant promise for the treatment of genetic disorders, allowing for precise modifications to an individual's genome to correct disease-causing mutations [52].

The use of wearable health technologies and mobile health applications will also play an increasingly important role in precision medicine, providing real-time health data that can be integrated into personalized care plans [53]. These devices have the potential to revolutionize disease prevention and management by allowing for continuous monitoring of an individual's health status and early detection of abnormalities [54].

## **International Collaboration in Precision Medicine**

Global collaboration is essential for the advancement of precision medicine, particularly in terms of data sharing and standardizing practices. International initiatives, such as the Global Alliance for Genomics and Health (GA4GH), aim to create a global framework for sharing genomic and clinical data, ensuring that precision medicine can be implemented across diverse populations [55]. Collaboration between countries will be vital in addressing the disparities in access to precision medicine, particularly in resource-limited settings where the necessary infrastructure and expertise may be lacking [56].

Standardization of data collection and analysis methods across countries is another critical factor in advancing precision medicine. By developing global standards for genomic data, healthcare systems can ensure consistency and accuracy in diagnoses and treatments, further enhancing the effectiveness of personalized medicine [57].



## **The Role of Policy and Regulation**

As precision medicine continues to evolve, governments and regulatory bodies will need to implement policies that support its growth while ensuring patient safety and privacy. Regulatory frameworks must be developed to address the unique challenges posed by precision medicine, including the ethical use of genetic data and the approval of personalized therapies [58]. Furthermore, policymakers must consider how to balance the rapid pace of innovation with the need for thorough testing and validation of new treatments [59].

Reimbursement policies are another key consideration, as the high costs associated with genomic testing and targeted therapies can be prohibitive for patients and healthcare systems alike. Governments and insurance companies will need to develop reimbursement models that make precision medicine more affordable and accessible to a wider population [60].

## **Challenges in Data Integration and Interpretation**

One of the biggest hurdles facing precision medicine is the challenge of integrating and interpreting the vast amounts of data generated through genomic sequencing, electronic health records, and wearable devices. Advanced computational tools and bioinformatics are essential for processing this data and translating it into actionable insights for personalized treatment plans [61]. However, the development of such tools is still in its early stages, and significant improvements are needed to ensure that clinicians can make sense of the data and apply it effectively in patient care [62].

Furthermore, data privacy remains a pressing concern, particularly as more personal health information is collected and stored digitally. Ensuring the security of this data and preventing unauthorized access will be critical in maintaining public trust in precision medicine [63].

## **Precision Medicine in Rare Diseases**

Precision medicine offers significant potential in the treatment of rare diseases, which often have a genetic basis. For patients with rare genetic disorders, precision medicine provides opportunities for targeted therapies tailored to the specific genetic mutations driving their conditions [64]. Advances in genomic sequencing have facilitated the diagnosis of many rare diseases that were previously undiagnosed, allowing for more precise and effective treatments [65]. In some cases, precision medicine approaches have led to life-saving interventions, providing hope for patients with rare diseases who previously had few treatment options [66].

However, the rarity of these conditions poses unique challenges for precision medicine, particularly in terms of research and development. The small patient populations make it difficult to conduct large-scale clinical trials, and the high costs associated with developing therapies for rare diseases can limit the availability of treatments [67]. Collaboration between researchers, pharmaceutical companies, and governments is essential to overcome these challenges and ensure that patients with rare diseases benefit from precision medicine advancements [68].

## **Personalized Medicine in Infectious Diseases**


Precision medicine is also expanding its reach into the treatment of infectious diseases. By analyzing the genetic makeup of both the patient and the pathogen, precision medicine can inform the selection of the most effective treatments and reduce the risk of drug resistance [69]. For example, genomic analysis of the hepatitis C virus has led to the development of highly effective antiviral therapies tailored to the specific viral genotypes [70].

Additionally, precision medicine plays a critical role in the management of antibiotic resistance, one of the greatest challenges in infectious disease treatment. By identifying the genetic mechanisms that confer resistance in pathogens, researchers can develop new strategies to combat resistant infections and optimize antibiotic use [71]. This approach helps ensure that the right drug is given at the right dose and time, minimizing the risk of resistance development [72].

Precision medicine is transforming the landscape of healthcare, providing personalized treatment options that are tailored to the unique genetic, environmental, and lifestyle factors of each patient. From oncology to cardiovascular disease, rare diseases, and infectious diseases, precision medicine has demonstrated its potential to improve patient outcomes and revolutionize disease treatment. However, significant challenges remain, including issues of data integration, ethical concerns, cost, and equitable access.

The future of precision medicine will depend on continued advancements in genomics, artificial intelligence, and bioinformatics, as well as the development of robust policies and regulatory frameworks that support its growth while ensuring patient safety. As technology continues to evolve and interdisciplinary collaboration strengthens, precision medicine is poised to become a central

component of modern healthcare, offering the promise of more effective, individualized treatments for a wide range of diseases [73].



**Fig.3. This diagram showcases the various fields where precision medicine is being applied.**

### **Personalized Medicine in Pediatrics**

Precision medicine holds particular promise in the field of pediatrics, where early diagnosis and intervention can significantly impact long-term health outcomes. Pediatric patients with genetic disorders or congenital conditions can benefit from treatments tailored to their specific genetic profiles, allowing for more effective and less invasive therapies [74]. For instance, precision medicine has been instrumental in identifying genetic mutations that cause rare metabolic diseases, leading to the development of targeted treatments that significantly improve quality of life for affected children [75].

Furthermore, early intervention in childhood can potentially prevent the onset of diseases later in life, offering opportunities for long-term disease prevention. For example, pediatric genomic screening may identify children at high risk for developing conditions such as diabetes, cardiovascular disease, or certain cancers, allowing for early lifestyle interventions and monitoring [76]. However, challenges remain in the implementation of precision medicine in pediatric care, including ethical concerns about genetic testing in children and the need for specialized pediatric genomic data [77].

### **The Role of Patient Advocacy in Precision Medicine**

Patient advocacy has become an increasingly important aspect of precision medicine, particularly in the treatment of rare diseases and conditions where patient populations are small and research funding may be limited. Patient advocacy groups have played a key role in raising awareness, securing funding, and advocating for policy changes that support the development of precision medicine treatments [78]. These groups often collaborate with researchers and pharmaceutical companies to drive innovation and ensure that the voices of patients are heard in the development of new therapies [79].

Moreover, patient advocates have been instrumental in promoting the importance of data sharing and participation in clinical trials, both of which are critical for the advancement of precision medicine. By engaging with diverse patient populations and encouraging participation in research, patient advocacy groups help ensure that precision medicine is accessible and equitable for all patients, regardless of socioeconomic status or geographic location [80].

### **DISCLOSURE**

The authors declare that there is no conflict of interest regarding the publication of this article. All research and findings discussed in this paper are based on a comprehensive review of current literature, and no financial or personal relationships influenced the content presented.

### **CONCLUSION**

Precision medicine is transforming healthcare by personalizing treatment to the unique genetic, environmental, and lifestyle factors of each patient. While technological advancements like AI, genomics, and big data analytics have greatly enhanced the precision of diagnosis and treatment, significant challenges remain. These include ethical concerns, economic disparities, and the need for widespread education and collaboration.

As the field of precision medicine continues to evolve, it will be crucial to address these barriers to realize its full potential. International collaboration, equitable access to technology, and the development of robust regulatory frameworks will be key to ensuring that precision medicine becomes a central part of modern healthcare. The future holds promise for more effective, personalized treatments that could revolutionize patient care across a wide range of diseases, from oncology to cardiovascular disease and beyond.



## APPENDICES

### Appendix A: Acronyms and Abbreviations

- AI: Artificial Intelligence
- ML: Machine Learning
- EHR: Electronic Health Records
- CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats

### Appendix B: Key Technologies in Precision Medicine

- Genomic Sequencing: A technology used to determine the sequence of DNA, crucial in identifying genetic variants related to diseases.
- Big Data Analytics: The analysis of large datasets such as EHRs to extract meaningful patterns in patient health.
- CRISPR/Cas9: A gene-editing technology that allows precise modifications in the genome.
- Wearable Devices: Health-monitoring devices that provide real-time data, which can be integrated into personalized healthcare plans.

## REFERENCES

1. Kosorok, M. R., & Laber, E. B. (2019). Precision medicine. *Annual Review of Statistics and Its Application*, 6(1), 263-286. <https://doi.org/10.1146/annurev-statistics-030718-105251>
2. König, I. R., Fuchs, O., Hansen, G., et.al. (2017). What is precision medicine? *European Respiratory Journal*, 50(4), 1700391. <https://doi.org/10.1183/13993003.00391-2017>
3. Mirnezami, R., Nicholson, J., & Darzi, A. (2012). Preparing for precision medicine. *The New England Journal of Medicine*, 366(6), 489-491. <https://doi.org/10.1056/NEJMp1114866>
4. Ginsburg, G. S., & Phillips, K. A. (2018). Precision medicine: From science to value. *Health Affairs*, 37(5), 694-701. <https://doi.org/10.1377/hlthaff.2017.1624>
5. Leopold, J. A., & Loscalzo, J. (2018). Emerging role of precision medicine in cardiovascular disease. *Circulation Research*, 122(9), 1302-1315. <https://doi.org/10.1161/CIRCRESAHA.117.310782>
6. Colijn, C., Jones, N., Johnston, I., Yaliraki, S. N., & Barahona, M. (2017). Toward precision healthcare: Context and mathematical challenges. *Frontiers in Physiology*, 8, 136. <https://doi.org/10.3389/fphys.2017.00136>
7. Delpierre, C., & Lefèvre, T. (2023). Precision and personalized medicine: What their current definition says and silences about the model of health they promote. *Frontiers in Sociology*, 8, 1112159. <https://doi.org/10.3389/fsoc.2023.1112159>
8. Faulkner, E., Holtorf, A. P., Walton, S., Liu, C. Y., & Payne, K. (2020). Being precise about precision medicine: What should value frameworks incorporate to address precision medicine? *Value in Health*, 23(5), 529-539. <https://doi.org/10.1016/j.jval.2019.11.010>
9. Kosorok, M. R., & Laber, E. B. (2019). Precision medicine. *Annual Review of Statistics and Its Application*, 6(1), 263-286. <https://doi.org/10.1146/annurev-statistics-030718-105251>
10. Ginsburg, G. S., & Phillips, K. A. (2018). Precision medicine: From science to value. *Health Affairs*, 37(5), 694-701. <https://doi.org/10.1377/hlthaff.2017.1624>
11. Leopold, J. A., & Loscalzo, J. (2018). Emerging role of precision medicine in cardiovascular disease. *Circulation Research*, 122(9), 1302-1315. <https://doi.org/10.1161/CIRCRESAHA.117.310782>
12. Konstantinidou, M., Karaglani, M., Panagopoulou, M., et.al (2017). Are the origins of precision medicine found in the Corpus Hippocraticum? *Molecular Diagnosis & Therapy*, 21(5), 601-606. <https://doi.org/10.1007/s40291-017-0291-y>
13. Naithani, N., Sinha, S., Misra, P., et.al. (2021). Precision medicine: Concept and tools. *Medical Journal Armed Forces India*, 77(3), 249-257. <https://doi.org/10.1016/j.mjafi.2021.06.021>
14. Mohsen, F., Al-Saadi, B., Abdi, N., Khan, S., & Shah, Z. (2023). Artificial intelligence-based methods for precision cardiovascular medicine. *Journal of Personalized Medicine*, 13(8), 1268. <https://doi.org/10.3390/jpm13081268>
15. Xu, S., Kim, J., Walter, J., Ghaffari, R., & Rogers, J. A. (2022). Translational gaps and opportunities for medical wearables in digital health. *Science Translational Medicine*, 14(603), abn6036. <https://doi.org/10.1126/scitranslmed.abn6036>





16. Wei, C. Y., Lee, M. T. M., & Chen, Y. T. (2012). Pharmacogenomics of adverse drug reactions: Implementing personalized medicine. *Human Molecular Genetics*, 21(R1), R58-65. <https://doi.org/10.1093/hmg/dds341>
17. Huddart, R., Sangkuhl, K., Whirl-Carrillo, M., & Klein, T. E. (2019). Are randomized controlled trials necessary to establish the value of implementing pharmacogenomics in the clinic? *Clinical Pharmacology & Therapeutics*, 106(1), 120-122. <https://doi.org/10.1002/cpt.1420>
18. Korngiebel, D. M., Thummel, K. E., & Burke, W. (2017). Implementing precision medicine: The ethical challenges. *Trends in Pharmacological Sciences*, 38(1), 8-14. <https://doi.org/10.1016/j.tips.2016.11.007>
19. Landry, L. G., Ali, N., Williams, D. R., Rehm, H. L., & Bonham, V. L. (2018). Lack of diversity in genomic databases is a barrier to translating precision medicine research into practice. *Health Affairs*, 37(5), 780-785. <https://doi.org/10.1377/hlthaff.2017.1595>
20. Neuhaus, C. P., Pacia, D. V., Crane, J. M., Maschke, K. J., & Berlinger, N. (2023). All of us and the promise of precision medicine: Achieving equitable access for federally qualified health center patients. *Journal of Personalized Medicine*, 13(4), 615. <https://doi.org/10.3390/jpm13040615>
21. Jeong, I., Bychkov, D., & Searson, P. C. (2019). Wearable devices for precision medicine and health state monitoring. *IEEE Transactions on Biomedical Engineering*, 66(4), 1242-1258. <https://doi.org/10.1109/TBME.2018.2871638>
22. Binnie, A., Fernandes, E., Almeida-Lousada, H., Mello, R., & Castelo-Branco, P. (2021). CRISPR-based strategies in infectious disease diagnosis and therapy. *Infection*, 49(3), 377-385. <https://doi.org/10.1007/s15010-020-01554-w>
23. Liu, X., Luo, X., Jiang, C., & Zhao, H. (2019). Difficulties and challenges in the development of precision medicine. *Clinical Genetics*, 95(5), 569-574. <https://doi.org/10.1111/cge.13511>
24. Benton, M. C., Abraham, A., Labella, A., Rokas, A., & Capra, J. A. (2021). The influence of evolutionary history on human health and disease. *Nature Reviews Genetics*, 22(5), 269-283. <https://doi.org/10.1038/s41576-020-00305-9>
25. Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2022). Review of precision cancer medicine: Evolution of the treatment paradigm. *Cancer Treatment Reviews*, 71, 50-58. <https://doi.org/10.1016/j.ctrv.2018.06.002>
26. Sharma, P., & Allison, J. P. (2015). Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. *Cell*, 161(2), 205-214. <https://doi.org/10.1016/j.cell.2015.03.030>
27. Leopold, J. A., & Loscalzo, J. (2018). Emerging role of precision medicine in cardiovascular disease. *Circulation Research*, 122(9), 1302-1315. <https://doi.org/10.1161/CIRCRESAHA.117.310782>
28. Johnson, J. A., & Cavallari, L. H. (2015). Pharmacogenetics and cardiovascular disease: Implications for personalized medicine. *Pharmacological Reviews*, 67(1), 142-158. <https://doi.org/10.1124/pr.114.009084>
29. Glicksberg, B. S., Johnson, K. W., & Dudley, J. T. (2018). The next generation of precision medicine: Observational studies, electronic health records, biobanks and continuous monitoring. *Human Molecular Genetics*, 27(R1), R56-R62. <https://doi.org/10.1093/hmg/ddy114>
30. Xu, S., Kim, J., Walter, J., Ghaffari, R., & Rogers, J. A. (2022). Translational gaps and opportunities for medical wearables in digital health. *Science Translational Medicine*, 14(603), abn6036. <https://doi.org/10.1126/scitranslmed.abn6036>
31. Schroll, M., Agarwal, A., Foroughi, O., Kong, E., & Perez, O. (2022). Stakeholders' perceptions of barriers to precision medicine adoption in the United States. *Journal of Personalized Medicine*, 12(7), 1025. <https://doi.org/10.3390/jpm12071025>
32. Schaibley, V. L., Ramos, I. M., Woosley, R. L., Curry, S. C., Hays, S. A., & Ramos, K. S. (2022). Limited genomics training among physicians remains a barrier to genomics-based implementation of precision medicine. *Frontiers in Medicine*, 9, 757212. <https://doi.org/10.3389/fmed.2022.757212>
33. Whitcomb, D. C. (2019). Barriers and research priorities for implementing precision medicine. *Pancreas*, 48(1), 127-135. <https://doi.org/10.1097/MPA.0000000000001415>
34. Dolan, D. M., Cho, M. K., & Lee, S. S. (2023). Innovating for a just and equitable future in genomic and precision medicine research. *The American Journal of Bioethics*, 23(1), 1-4. <https://doi.org/10.1080/15265161.2023.2215201>
35. Love-Koh, J., Peel, A., Rejon-Parrilla, J. C., Ennis, K., Lovett, R., & Manca, A. (2018). The future of precision medicine: Potential impacts for health technology assessment. *Pharmacoeconomics*, 36(12), 1439-1451. <https://doi.org/10.1007/s40273-018-0686-6>
36. Landry, L. G., Ali, N., Williams, D. R., Rehm, H. L., & Bonham, V. L. (2018). Lack of diversity in genomic databases is a barrier to translating precision medicine research into practice. *Health Affairs*, 37(5), 780-785. <https://doi.org/10.1377/hlthaff.2017.1595>
37. Bilkey, G. A., Burns, B. L., Coles, E. P., Mahede, T., Baynam, G. S., & Nowak, K. J. (2019). Optimizing precision medicine for public health. *Frontiers in Public Health*, 7, 42. <https://doi.org/10.3389/fpubh.2019.00042>
38. Baldwin, H. M., Loebel-Davidson, L., Oliver, D., Pablo, G. S., Stahl, D., & Riper, H. (2022). Real-world implementation of precision psychiatry: A systematic review of barriers and facilitators. *Brain Sciences*, 12(7), 934. <https://doi.org/10.3390/brainsci12070934>
39. Tan, M. K. H., Xu, Y., Gao, Z., Yuan, T., Liu, Q., Yang, R., Zhang, B., & Peng, L. (2022). Recent advances in intelligent wearable medical devices integrating biosensing and drug delivery. *Advanced Materials*, 34(12), 108491. <https://doi.org/10.1002/adma.202108491>



40. Binnie, A., Fernandes, E., Almeida-Lousada, H., Mello, R., & Castelo-Branco, P. (2021). CRISPR-based strategies in infectious disease diagnosis and therapy. *Infection*, 49(3), 377-385. <https://doi.org/10.1007/s15010-020-01554-w>
41. Kampmann, M. (2018). CRISPRi and CRISPRa screens in mammalian cells for precision biology and medicine. *ACS Chemical Biology*, 13(2), 406-416. <https://doi.org/10.1021/acscchembio.7b00657>
42. Benton, M. C., Abraham, A., Labella, A., Rokas, A., & Capra, J. A. (2021). The influence of evolutionary history on human health and disease. *Nature Reviews Genetics*, 22(5), 269-283. <https://doi.org/10.1038/s41576-020-00305-9>
43. Korngiebel, D. M., Thummel, K. E., & Burke, W. (2017). Implementing precision medicine: The ethical challenges. *Trends in Pharmacological Sciences*, 38(1), 8-14. <https://doi.org/10.1016/j.tips.2016.11.007>
44. Ahmed, Z., Mohamed, K., Zeeshan, S., & Dong, X. (2020). Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. *Database: The Journal of Biological Databases and Curation*, 2020, baaa010. <https://doi.org/10.1093/database/baaa010>
45. Bilkey, G. A., Burns, B. L., Coles, E. P., Mahede, T., Baynam, G. S., & Nowak, K. J. (2019). Optimizing precision medicine for public health. *Frontiers in Public Health*, 7, 42. <https://doi.org/10.3389/fpubh.2019.00042>
46. Erdmann, A., Rehmann-Sutter, C., & Bozzaro, C. (2021). Patients' and professionals' views related to ethical issues in precision medicine: A mixed research synthesis. *BMC Medical Ethics*, 22(1), 82. <https://doi.org/10.1186/s12910-021-00682-8>
47. Nindra, U., Pal, A., & Lee, C. (2023). Precision medicine in Australia: Now is the time to get it right. *Medical Journal of Australia*, 218(3), 97-99. <https://doi.org/10.5694/mja2.51887>
48. Menon, U., Ashing, K., Chang, M., Christy, S., Friberg-Felsted, K., & Alcaraz, K. (2019). Application of the ConNECT framework to precision health and health disparities. *Nursing Research*, 68(2), 99-109. <https://doi.org/10.1097/NNR.0000000000000329>
49. Dolan, D. M., Cho, M. K., & Lee, S. S. (2023). Innovating for a just and equitable future in genomic and precision medicine research. *The American Journal of Bioethics*, 23(1), 1-4. <https://doi.org/10.1080/15265161.2023.2215201>
50. Ginsburg, G. S., & Phillips, K. A. (2018). Precision medicine: From science to value. *Health Affairs*, 37(5), 694-701. <https://doi.org/10.1377/hlthaff.2017.1624>
51. Xu, J., Sram, R. J., Cebulska-Wasilewska, A., Miloradov, M., Şardaş, Ş., & Au, W. W. (2020). Challenge-comet assay: A functional and genomic biomarker for precision risk assessment and disease prevention among exposed workers. *Toxicology and Applied Pharmacology*, 400, 115011. <https://doi.org/10.1016/j.taap.2020.115011>
52. Xing, H., & Meng, L. (2019). CRISPR-Cas9: A powerful tool towards precision medicine in cancer treatment. *Acta Pharmacologica Sinica*, 41(5), 583-587. <https://doi.org/10.1038/s41401-019-0322-9>
53. Schoger, E., Lelek, S., Panáková, D., & Zelarayán, L. (2022). Tailoring cardiac synthetic transcriptional modulation towards precision medicine. *Frontiers in Cardiovascular Medicine*, 8, 783072. <https://doi.org/10.3389/fcvm.2021.783072>
54. Jin, X., Liu, C., Xu, T., Su, L., & Zhang, X. (2020). Artificial intelligence biosensors: Challenges and prospects. *Biosensors and Bioelectronics*, 165, 112412. <https://doi.org/10.1016/j.bios.2020.112412>
55. Global Alliance for Genomics and Health. (2021). Data sharing for genomic research. <https://genomicsandhealth.org/>
56. Gray, M., Lagerberg, T., & Dombrádi, V. (2017). Equity and value in precision medicine. *The New Bioethics*, 23(1), 87-94. <https://doi.org/10.1080/20502877.2017.1314891>
57. Neuhaus, C. P., Pacia, D. V., Crane, J. M., Maschke, K. J., & Berlinger, N. (2023). All of us and the promise of precision medicine: Achieving equitable access for federally qualified health center patients. *Journal of Personalized Medicine*, 13(4), 615. <https://doi.org/10.3390/jpm13040615>
58. Kessler, C. (2018). Genomics and precision medicine. *AACN Advanced Critical Care*, 29(1), 26-27. <https://doi.org/10.4037/aacnacc2018823>
59. Clayton, T. A., Lindon, J. C., Cloarec, O., Antti, H., Charuel, C., Hanton, G., ... & Nicholson, J. K. (2006). Pharmacometabonomic phenotyping and personalized drug treatment. *Nature*, 440(7087), 1073-1077. <https://doi.org/10.1038/nature04648>
60. Faulkner, E., Holtorf, A. P., Walton, S., Liu, C. Y., Lin, H., & Payne, K. (2020). Being precise about precision medicine: What should value frameworks incorporate to address precision medicine? *Value in Health*, 23(5), 529-539. <https://doi.org/10.1016/j.jval.2019.11.010>
61. Glicksberg, B. S., Johnson, K. W., & Dudley, J. T. (2018). The next generation of precision medicine: Observational studies, electronic health records, biobanks, and continuous monitoring. *Human Molecular Genetics*, 27(R1), R56-R62. <https://doi.org/10.1093/hmg/ddy114>
62. Ho, D., Schierding, W., Wake, M., Saffery, R., & O'Sullivan, J. (2019). Machine learning SNP-based prediction for precision medicine. *Frontiers in Genetics*, 10, 267. <https://doi.org/10.3389/fgene.2019.00267>
63. Winkler, E. C., & Knoppers, B. M. (2020). Ethical challenges of precision cancer medicine. *Seminars in Cancer Biology*, 20, 199-209. <https://doi.org/10.1016/j.semcancer.2020.09.009>
64. Malla, M. A., Dubey, A., Kumar, A., Yadav, S., Hashem, A., & Abd\_Allah, E. F. (2019). Exploring the human microbiome: The potential future role of next-generation sequencing in disease diagnosis and treatment. *Frontiers in Immunology*, 9, 2868. <https://doi.org/10.3389/fimmu.2018.02868>
65. Mirnezami, R., Nicholson, J., & Darzi, A. (2012). Preparing for precision medicine. *The New England Journal of Medicine*, 366(6), 489-491. <https://doi.org/10.1056/NEJMp1114866>



66. Rajpoot, M., Sharma, A., Sharma, A., & Gupta, G. (2018). Understanding the microbiome: Emerging biomarkers for exploiting the microbiota for personalized medicine against cancer. *Seminars in Cancer Biology*, 52(1), 1-8. <https://doi.org/10.1016/j.semcancer.2018.02.003>
67. Brew-Sam, N., Parkinson, A., Lueck, C., Brown, E., Bruestle, A., & Collins, S. (2022). The current understanding of precision medicine and personalized medicine in selected research disciplines: Study protocol of a systematic concept analysis. *BMJ Open*, 12, e060326. <https://doi.org/10.1136/bmjopen-2021-060326>
68. Franks, P. W., & Poveda, A. (2021). Precision medicine in type 2 diabetes: An implementation road map. *Journal of Internal Medicine*, 290(6), 881-901. <https://doi.org/10.1111/joim.13271>
69. MacEachern, S. J., & Forkert, N. D. (2020). Machine learning for precision medicine. *Genome*, 63(4), 221-230. <https://doi.org/10.1139/gen-2020-0131>
70. Vázquez-Baeza, Y., Callewaert, C., Debelius, J., Hyde, E., & Knight, R. (2018). Impacts of the human gut microbiome on therapeutics. *Annual Review of Pharmacology and Toxicology*, 58(1), 253-270. <https://doi.org/10.1146/annurev-pharmtox-042017-031849>
71. Raj, M., Keshava, V., & Dadgar, N. (2023). The influence of the microbiome on immunotherapy for gastroesophageal cancer. *Cancers*, 15(18), 4426. <https://doi.org/10.3390/cancers15184426>
72. Laudes, M., Geisler, C., Rohmann, N., Bouwman, J., Pischon, T., & Schlicht, K. (2021). Microbiota in health and disease—Potential clinical applications. *Nutrients*, 13(11), 3866. <https://doi.org/10.3390/nu13113866>
73. Malla, M. A., Dubey, A., Kumar, A., Yadav, S., Hashem, A., & Abd\_Allah, E. F. (2019). Exploring the human microbiome: The potential future role of next-generation sequencing in disease diagnosis and treatment. *Frontiers in Immunology*, 9, 2868. <https://doi.org/10.3389/fimmu.2018.02868>
74. Bentzon, J. F., Otsuka, F., Virmani, R., & Falk, E. (2014). Mechanisms of plaque formation and rupture. *Circulation Research*, 114(12), 1852-1866. <https://doi.org/10.1161/CIRCRESAHA.114.302721>
75. Pirmohamed, M. (2014). Personalized pharmacogenomics: Predicting efficacy and adverse drug reactions. *Annual Review of Genomics and Human Genetics*, 15(1), 349-370. <https://doi.org/10.1146/annurev-genom-090413-025419>
76. Mirnezami, R., Nicholson, J., & Darzi, A. (2012). Preparing for precision medicine. *The New England Journal of Medicine*, 366(6), 489-491. <https://doi.org/10.1056/NEJMp1114866>
77. Sadee, W., Wang, D., Hartmann, K., & Toland, A. E. (2023). Pharmacogenomics: Driving personalized medicine. *Pharmacological Reviews*, 75(4), 789-814. <https://doi.org/10.1124/pharmrev.122.000810>
78. Bilkey, G. A., Burns, B. L., Coles, E. P., Mahede, T., Baynam, G. S., & Nowak, K. J. (2019). Optimizing precision medicine for public health. *Frontiers in Public Health*, 7, 42. <https://doi.org/10.3389/fpubh.2019.00042>
79. Dolan, D. M., Cho, M. K., & Lee, S. S. (2023). Innovating for a just and equitable future in genomic and precision medicine research. *The American Journal of Bioethics*, 23(1), 1-4. <https://doi.org/10.1080/15265161.2023.2215201>
80. Menon, U., Ashing, K., Chang, M., Christy, S., Friberg-Felsted, K., & Alcaraz, K. (2019). Application of the ConNECT framework to precision health and health disparities. *Nursing Research*, 68(2), 99-109. <https://doi.org/10.1097/NNR.0000000000000329>

How to cite this article:

Felic. S et al. *Ijppr.Human*, 2024; Vol. 30 (10): 127-137.

Conflict of Interest Statement: All authors have nothing else to disclose.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.